At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 753 enrolled
Drug / intervention
Meningococcal vaccine GSK 134612 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine (GSK 134612) When Co-administered With Routine Vaccines in Healthy Infants and Toddlers
In Brief
A Phase 3 clinical trial evaluating Meningococcal vaccine GSK 134612, SynflorixTM, and 1 other intervention for Meningococcal Infection. Completed, enrolled 753 participants across 2 sites in 2 countries.
Detailed Summary
This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK 134612 in healthy infants, when co-administered with other infant vaccines, on three different dose schedules.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningococcal Infection
CountriesLebanon, Mexico
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2011
Enrollment StartJan 2012
Primary CompletionAug 2014
Study CompletionOct 2015
TodayJul 2026
First PostedApr 25, 2011
Enrollment StartJan 27, 2012
Primary CompletionAug 4, 2014
Study CompletionOct 19, 2015
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 15.2 years ago
Interventions
Meningococcal vaccine GSK 134612biological
Intramuscular injection
SynflorixTMbiological
Intramuscular injection
Infanrix-IPV/HiberixTMbiological
Intramuscular injection